Petros Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Petros Pharmaceuticals, Inc. (PTPI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $112.53 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $11.20K, a 67.62% decline year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $28.81K, a 14.10% decline year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $36.83K, a 13.21% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $35.69K, a 13.12% increase year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $112.53K, a 14.89% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $132.21K, a 12.92% increase from fiscal 2022.
- Petros Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $117.08K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $11.20K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $40.01K derived: sum of 2 quarters · filed 2025-03-31 | $76.84K derived: sum of 3 quarters · filed 2025-03-31 | $112.53K 10-K · filed 2025-03-31 |
| 2024-09-30 | $28.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $65.64K derived: sum of 2 quarters · filed 2024-11-13 | $101.33K 10-Q · filed 2024-11-13 | $135.92K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $36.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $72.52K 10-Q · filed 2024-08-14 | $107.11K derived: sum of 3 quarters · filed 2025-03-31 | $140.65K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $35.69K 10-Q · filed 2024-05-15 | $70.28K derived: sum of 2 quarters · filed 2025-03-31 | $103.82K derived: sum of 3 quarters · filed 2025-03-31 | $136.35K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $34.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $68.13K derived: sum of 2 quarters · filed 2025-03-31 | $100.66K derived: sum of 3 quarters · filed 2025-03-31 | $132.21K 10-K · filed 2025-03-31 |
| 2023-09-30 | $33.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $66.07K derived: sum of 2 quarters · filed 2024-11-13 | $97.62K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $32.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $64.08K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $31.55K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $117.08K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |